High cholesterol levels are common and can be a fatal health problem, but new drugs could help more people manage the condition. It has been shown to lower levels of “bad” cholesterol by 60% in phase clinical trials.
The new drug, known as MK-0616, works by blocking a protein called PCSK9. Low levels of PCSK9 help the liver break down low-density lipoprotein (LDL) cholesterol. PCSK9 inhibitors have been the mainstay of therapy for lowering cholesterol, but usually require subcutaneous injections and, in some studies, gene therapy.
A new trial investigated the efficacy of MK-0616 as an oral PCSK9 inhibitor. Over 380 participants were enrolled, all of whom had high levels of LDL cholesterol and a history of heart disease or its risk factors. Participants were randomly assigned to one of five groups (12 mg, 18 mg, or 30 mg). LDL cholesterol levels were measured at 12:00 and continued to be monitored for side effects for an additional 8 weeks.
Sure enough, participants who took the drug had significantly lower LDL cholesterol levels compared to placebo. decreased by 41%. Other biomarkers of bad cholesterol also decreased, including non-HDL cholesterol and her protein called ApoB. Importantly, the team found no evidence of adverse side effects at any dose.
Further trials are needed to explore MK-0616 in more detail, but the team says the drug is a promising new addition to the arsenal of cardiovascular care. were taking them during the trial, they work well in combination with statins, which are first-line treatments for high cholesterol. can be reduced.
“This is a well-tolerated and highly effective compound. MK-0616 may offer another potential option. Between, we should be able to basically treat almost anyone with LDL cholesterol.”
Phase 3 clinical trials are currently being planned. This research Journal of the American College of Cardiology.
Source: American College of Cardiology
